The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...

Hundreds of people with cystic fibrosis are to be offered a once-a-day pill which has been hailed as “life changing” by health experts.

Businesses have always relied on data, but they never were able to get full value out of them when they were siloed by structure, system, or storage.